Search

Sartorius Stedim Biotech.

Closed

SectorFinance

178.2 2.53

Overview

Share price change

24h

Current

Min

178.2

Max

179.2

Key metrics

By Trading Economics

Income

4.9M

93M

Sales

4.2M

766M

P/E

Sector Avg

56.921

19.1

EPS

1.25

Dividend yield

0.41

Profit margin

12.146

Employees

10,477

EBITDA

9.2M

240M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+29.29% upside

Dividends

By Acuity

Dividend yield

Sector Avg

0.41%

4.56%

Next Earnings

22 Oct 2026

Market Stats

By TradingEconomics

Market Cap

-808M

17B

Previous open

175.67

Previous close

178.2

News Sentiment

By Acuity

13%

87%

17 / 438 Finance

Sartorius Stedim Biotech. Chart

Past performance is not a reliable indicator of future results.

Related News

7 Aug 2026, 23:56 UTC

News

Sweetgreen shares declined in after-market trading as multiple analysts lowered price targets, with UBS and RBC both setting targets at $6.50.

7 Aug 2026, 23:46 UTC

News

JetBlue Airways reports wider net loss and updates operating guidance. Shares are lower in after-market trading following the $121.4 million shelf registration.

7 Aug 2026, 23:46 UTC

News

Etsy Inc shares are lower in after-market hours following its Q2 results, which showed a double beat but faced revenue challenges from divestments.

7 Aug 2026, 23:46 UTC

News

Cogent Communications is trading lower in after-market hours amid a class action lawsuit alleging securities fraud by Pomerantz LLP and ongoing operational challenges.

7 Aug 2026, 23:41 UTC

News

ResMed shares declined after-market despite RBC Capital raising its price target to $244 and maintaining a Sector Perform rating.

7 Aug 2026, 23:41 UTC

News

Mitek Systems reported an 18% revenue increase in Q3, with shares advancing in after-market hours, despite earlier pulling back from a session high.

7 Aug 2026, 23:36 UTC

News

Tripadvisor Inc announced participation in two investor conferences, enhancing engagement with investors. Shares are trading slightly higher in after-market hours.

7 Aug 2026, 23:36 UTC

News

Shift4 Payments lowers 2026 outlook, adjusting full-year revenue guidance down by about 200 basis points. Shares are trading lower in after-market hours.

7 Aug 2026, 23:36 UTC

News

Epam Systems shares are trading lower in after-market hours following TD Cowen's price target cut to $120, despite earlier gains in the session.

7 Aug 2026, 23:31 UTC

News

Arcutis Biotherapeutics granted 143,500 RSUs and options to new hires. Shares are trading higher in after-market hours following the announcement.

7 Aug 2026, 23:31 UTC

News

Figs Inc reported strong Q2 earnings but is trading lower in after-market hours as Telsey Advisory Group lowered its price target to $16.

7 Aug 2026, 23:31 UTC

News

Ardelyx shares are higher in after-market trading as TD Cowen maintains a Buy rating and lowers the price target to $10.

7 Aug 2026, 23:31 UTC

News

Celsius Holdings is under investigation for potential securities law violations following disappointing second-quarter results, with shares trading lower in after-market hours.

7 Aug 2026, 23:26 UTC

News

Delta Air Lines is gaining after reporting strong second-quarter results and positive passenger traffic growth projections, with anticipated earnings of $6.63 per share.

7 Aug 2026, 23:26 UTC

News

Five9 Inc. reported second-quarter earnings of $0.70 per share and raised full-year revenue guidance to $1.27 billion. Shares are higher in after-market trading.

7 Aug 2026, 23:26 UTC

News

UBS raised its price target on Unity Software Inc. to $48, contributing to shares trading higher in after-market hours. Positive sentiment from tech stocks also supported this move.

7 Aug 2026, 23:26 UTC

Event
News

Scholar Rock Holding Corp reports FDA review progress for apitegromab, with a decision expected by September 30, 2026. Shares are trading higher in after-market hours.

7 Aug 2026, 23:26 UTC

News

Kraft Heinz Co reported second-quarter revenue of $6.26 billion, exceeding expectations. Shares rose in after-market trading amid positive sentiment and broader market strength.

7 Aug 2026, 23:26 UTC

News

Leidos Holdings shares are lower in after-market hours after TD Cowen raised the price target to $135 while maintaining a Hold rating.

7 Aug 2026, 23:21 UTC

News

MP Materials will participate in Canaccord Genuity's Growth Conference in August 2026. Shares are trading higher in after-market hours following the announcement.

7 Aug 2026, 23:21 UTC

News

TD Cowen raised its price target on Akamai Technologies to $140 while maintaining a Hold rating. Shares are higher in after-market trading.

7 Aug 2026, 23:21 UTC

Social Media
News
Event

Abcellera Biologics will release Phase 2 trial results for ABCL635 on August 10, 2026. Shares are sharply higher in after-market trading amid positive investor sentiment.

7 Aug 2026, 23:21 UTC

News

Halozyme Therapeutics reported strong Q2 earnings and raised guidance, yet shares are trading lower in after-market hours following notable weakness.

7 Aug 2026, 23:16 UTC

News

Hawaiian Electric Industries reported Q2 revenues of $939.70 million, but adjusted EPS of $0.13 missed estimates by $0.06. Shares are trading roughly flat in after-hours.

7 Aug 2026, 23:16 UTC

News

10X Genomics Inc shares are lower in after-market trading amid a sector decline. Citigroup raised its price target to $50 while maintaining a Neutral rating.

7 Aug 2026, 23:11 UTC

News

Ashland Inc. is exploring a potential sale amid takeover interest, while announcing a quarterly cash dividend of $0.42 per share. Shares lower in after-market trading.

7 Aug 2026, 23:06 UTC

News

Baker Hughes reported a stable U.S. rig count of 588, with oil rigs rising to 454 and gas rigs declining to 124. Shares were little changed in after-market trading.

7 Aug 2026, 23:06 UTC

News

Kimberly-Clark Corp shares are lower in after-market trading, reflecting ongoing challenges with revenue and margins amid rising input costs and competition.

7 Aug 2026, 23:06 UTC

News

Photronics Inc shares are lower in after-market trading following a class action lawsuit alleging misleading statements about its product pipeline and demand stability.

7 Aug 2026, 23:06 UTC

News

Morgan Stanley shares are lower after-market, reflecting a slight decline. The movement follows the bank's $400 million Bitcoin purchases amid uncertain market conditions.

Peer Comparison

Price change

Sartorius Stedim Biotech. Forecast

Price Target

By TipRanks

29.29% upside

12 Months Forecast

Average 230 EUR  29.29%

High 260 EUR

Low 210 EUR

Based on 5 Wall Street analysts offering 12 month price targets forSartorius Stedim Biotech. - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

5 ratings

4

Buy

1

Hold

0

Sell

Sentiment

By Acuity

17 / 438 Finance

News Sentiment

Very Strong Bullish Evidence

Volatility

Below average

News Volume (RCV)

Average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Sartorius Stedim Biotech.

Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, separation, purification, and fluid management services; biolayer interferometry instruments; microbiology enumeration, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; biomolecule analysis tools; flow cytometry; batch and intensified chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; and weighing products. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production; process automation platform and software; and develops and produces transfection, as well as other DNA/RNA delivery reagents and plasmid DNA. It serves manufacturers of medications, vaccines, foods, and chemicals, as well as research and development laboratories. The company was incorporated in 1978 and is headquartered in Aubagne, France. As of December 31, 2023, Sartorius Stedim Biotech S.A. operates as a subsidiary of Sartorius AG.
help-icon Live chat